Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 419

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 419
---
   769,092 |   |     |   |   672,374 |   |
| Operating lease liabilities, non-current                               |     |                    | 1,575,499 |   |     |   | 2,344,590 |   |
| Total operating lease liabilities                                      |     | $                  | 2,344,591 |   |     | $ | 3,016,964 |   |
| Weighted-average remaining lease term of operating leases (in years)   |     |                    |      2.75 |   |     |   |      3.75 |   |
| Weighted-average discount rate for operating leases                    |     |                    |      9.60 | % |     |   |      9.60 | % |

<div align='center'>F-60

CERo Therapeutics, Inc.

Notes to Financial Statements</div>

The interest expense related to leases was $260,848
and $320,790 for years ended December 31, 2023 and 2022, respectively.

The following table reconciles the undiscounted
future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one
year to the total operating lease liabilities recognized on the balance sheets as of December 31, 2023:

| Year ending December 31: 
 2024                     |     | Operating 
 Leases    |   961,218 |   |
|:-------------------------|:----|:----------|----------:|:--|
| 2025                     |     |           |   990,055 |   |
| 2026                     |     |           |   726,394 |   |
| Total lease payments     |     |           | 2,677,667 |   |
| Less                     
 imputed interest         |     |           |  (333,076 | ) |
| Total                    
 lease liabilities        |     | $         | 2,344,591 |   |

NOTE 7 – CONVERTIBLE PREFERRED STOCK

The Company had 75,120,105 shares of capital
stock authorized as of December 31, 2023 and 2022, consisting of 45,350,000 shares of common stock and 29,770,105 shares of convertible
preferred stock. All classes of the Company’s stock have a par value of $0.0001. On February 14,